HDAC9 and malaria: An in vivo efficacy study on a rodent malaria model with Plasmodium yoelii showed that only quisinostat among these five HDAC inhibitors remained effective in clearing P. yoelii blood-stage infections (Supplementary Fig. S1c), making quisinostat a lead compound for further research.